STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia

Leukemia

Volumn 27, Issue 11, 2013, Pages 2244-2247

  Ohgami, R S ^a   Ma, L ^a   Merker, J D ^a   Martinez, B ^a   Zehnder, J L ^a   Arber, D A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; FEMALE; GENE MUTATION; HUMAN; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE;

AGED; ANTIGENS, CD30; BONE MARROW; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LYMPH NODES; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SKIN; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84887320457     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.104     Document Type: Letter

References (9)

1. Levy DE, Inghirami G. STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006; 103: 10151-10152. (Pubitemid 44051135)
2. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448: 1058-1062. (Pubitemid 47345590)
3. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
4. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120: 3048-3057.
5. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V et al. Differential expression and clinical significance of tyrosine- phosphorylated STAT3 in ALK\+ and ALK-anaplastic large cell lymphoma. Clin Cancer Res 2003; 9(10 Pt 1): 3692-3699. (Pubitemid 37169237)
6. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001; 15: 787-793. (Pubitemid 32492702)
7. Ohgami RS, Ohgami JK, Pereira IT, Gitana G, Zehnder JL, Arber DA. Refining the diagnosis of T-cell large granular lymphocytic leukemia by combining distinct patterns of antigen expression with T-cell clonality studies. Leukemia 2011; 25: 1439-1443.
8. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629. (Pubitemid 40868302)
9. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005; 16: 601-607. (Pubitemid 40863092)